AEterna Zentaris (TSX:AEZS) Other Stockholders Equity : C$6.88 Mil (As of Mar. 2024)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Other Stockholders Equity?

AEterna Zentaris's Other Stockholders Equity for the quarter that ended in Mar. 2024 was C$6.88 Mil.

AEterna Zentaris's quarterly Other Stockholders Equity declined from Sep. 2023 (C$6.88 Mil) to Dec. 2023 (C$6.82 Mil) but then increased from Dec. 2023 (C$6.82 Mil) to Mar. 2024 (C$6.88 Mil).

AEterna Zentaris's annual Other Stockholders Equity declined from Dec. 2021 (C$121.44 Mil) to Dec. 2022 (C$6.91 Mil) and declined from Dec. 2022 (C$6.91 Mil) to Dec. 2023 (C$6.82 Mil).

AEterna Zentaris Other Stockholders Equity Historical Data

The historical data trend for AEterna Zentaris's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Other Stockholders Equity Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

Get a 7-Day Free Trial

118.27

130.53

121.44

6.91

6.82

AEterna Zentaris Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Stockholders Equity	Get a 7-Day Free Trial															130.58	6.76	6.88	6.82	6.88

AEterna Zentaris Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

AEterna Zentaris Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.